Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Glanzmann Thrombasthenia
Interventions
DRUG

EPTACOG BETA

"Eptacog beta (SEVENFACT®; EB) is a lyophilized powder in single-use vials (1, 2, or 5 mg) of coagulation factor VIIa (recombinant)-jncw. It is reconstituted with sterile water (provided in the kit) and administered intravenously.~SEVENFACT® may be administered by a healthcare provider (HCP) at the study site or home, or by a trained participant/caregiver. Participants will be monitored in a healthcare facility for 60 minutes after the first dose for hypersensitivity."

Trial Locations (1)

Georgia

"Arthur M. Blank Hospital , Children's Healthcare of Atlanta"

All Listed Sponsors
collaborator

Laboratoire Français du Fractionnement et des Biotechnologies (LFB BIOTECHNOLOGIES)

UNKNOWN

lead

Emory University

OTHER